Acute Myeloid Leukemia: 2021 Perspectives on Testing, Systemic Therapies, and Transplantation
EP. 1: Molecular Testing for Acute Myeloid Leukemia
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center,Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center Mark Levis, MD, PhD, leads a panel of experts in a discussion on factors to consider when ordering molecular testing for newly diagnosed and relapsed/refractory acute myeloid leukemia.
EP. 2: Molecular Testing Turnaround Time and Treatment Delay
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ,Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center Key opinion leaders in acute myeloid leukemia reflect on challenges associated with molecular testing by commenting on potential treatment delay from the long turnaround time (TAT) of next-generation sequencing.
EP. 3: The Role of FLT3 Inhibitors for Treatment of AML
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ,Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center Experts in hematologic malignancies provide key insights into the use of FLT3 inhibitors and discuss whether it is possible to predict patients who may benefit from midostaurin + chemotherapy.
EP. 4: Second-Generation FLT3 Inhibitors for Acute Myeloid Leukemia
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ,Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center A panel of thought leaders in AML examines single-agent and combination-based approaches using the second-generation FLT3 inhibitors gilteritinib, quizartinib, and crenolanib.
EP. 5: Combining and Sequencing FLT3 Inhibitors in AML
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ,Mark J. Levis, MD, PhD, Johns Hopkins University,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center Harry Erba, MD, PhD; Courtney DiNardo, MD; Mark Levis, MD, PhD; and Vinod Pullarkat, MD, review factors to consider when using combining and/or sequencing first- or second-generation FLT3 inhibitors for patients with acute myeloid leukemia (AML).
EP. 6: The Role of IDH Inhibitors for Treatment of AML
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ,Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center Harry Erba, MD, PhD; Courtney DiNardo, MD; and Dan Pollyea, MD, MS, discuss the role of the IDH inhibitors ivosidenib and enasidenib as single-agent or combination therapy in patients with acute myeloid leukemia (AML).
EP. 7: Toxicities Associated With IDH Inhibitors
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ,Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center A panel of key opinion leaders in acute myeloid leukemia reflects on the importance of considering the toxicity profiles of IDH inhibitors and emphasizes the challenges of diagnosing differentiation syndrome.
EP. 8: Combination Approaches Targeting FLT3 and IDH Mutations
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ,Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center Expert hematologist-oncologists share insights into clinical trials studying how to best combine or sequence FLT3 and IDH inhibitors in patients with both mutations.
EP. 9: Venetoclax Combination Therapy for IDH-mutated AML
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ,Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center Key opinion leader in the management of acute myeloid leukemia, Harry Erba, MD PhD, builds a conversation on the use of venetoclax as a part of combination therapy in patients with IDH mutations.
EP. 10: The Role of Venetoclax for Treatment of AML
ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ,Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center Renowned experts in hematology-oncology provide insight into the practical implications of treating acute myeloid leukemia with the current standard-of-care regimen using venetoclax.
EP. 11: Approaches to Managing Toxicity of Venetoclax
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ,Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center Courtney DiNardo, MD emphasizes the importance of understanding the risk of tumor lysis syndrome, monitoring for drug-drug interactions, and performing a bone marrow biopsy at the end of cycle 1 when treating AML with venetoclax.
EP. 12: The Role of Allogeneic Stem Cell Transplant in AML
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ,Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center Dan Pollyea, MD, MS provides a high-level overview of the role of allogeneic stem cell transplant at first remission based on risk stratification, highlighting how to select patients for transplant.
EP. 13: 5-Year Follow-up Data on CPX-351 for AML
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ,Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center A panel of specialists in hematology oncology review the 5-year follow-up data on the use of CPX-351 for adults and pediatric patients with acute myeloid leukemia.
EP. 14: Evolving Treatment Approaches Pre- and Post-Transplant
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ,Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center Vinod Pullarkat, MD, leads a detailed discussion on evolving treatment approaches using MRD pretransplant, and panelists consider recent therapeutic advances for the post-transplant setting.
EP. 15: Treatment Approaches for TP53-Mutated AML
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ,Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center Key opinion leaders in hematology oncology share insights into the challenges associated with treating patients with TP53-mutated AML and highlight the recent FDA breakthrough designation of eprenetapopt.
EP. 16: Final Thoughts on New Developments and Emerging Agents
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ,Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center Panelists conclude by reviewing possible advancements on the horizon in AML such as the potential emergence of Menin inhibitors and bispecific T-cell engagers as well as improved methods for predicting response and preventing relapse.
